MA41544A - Dosages de panobinostat pour le traitement du myélome multiple - Google Patents

Dosages de panobinostat pour le traitement du myélome multiple

Info

Publication number
MA41544A
MA41544A MA041544A MA41544A MA41544A MA 41544 A MA41544 A MA 41544A MA 041544 A MA041544 A MA 041544A MA 41544 A MA41544 A MA 41544A MA 41544 A MA41544 A MA 41544A
Authority
MA
Morocco
Prior art keywords
panobinostat
dosage
treatment
multiple myeloma
myeloma
Prior art date
Application number
MA041544A
Other languages
English (en)
Inventor
Florence Binlich
Renaud Capdeville
Laura Grazioli
Rong Lin
Song Mu
Sofia Paul
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55405393&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA41544(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA41544A publication Critical patent/MA41544A/fr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • A61K31/4045Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/69Boron compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407Specifically defined cancers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4858Organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4866Organic macromolecular compounds
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90Enzymes; Proenzymes
    • G01N2333/91Transferases (2.)
    • G01N2333/91188Transferases (2.) transferring nitrogenous groups (2.6)
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/08Hepato-biliairy disorders other than hepatitis
    • G01N2800/085Liver diseases, e.g. portal hypertension, fibrosis, cirrhosis, bilirubin
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
MA041544A 2015-02-19 2016-02-16 Dosages de panobinostat pour le traitement du myélome multiple MA41544A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562118254P 2015-02-19 2015-02-19
US201562119571P 2015-02-23 2015-02-23

Publications (1)

Publication Number Publication Date
MA41544A true MA41544A (fr) 2017-12-26

Family

ID=55405393

Family Applications (1)

Application Number Title Priority Date Filing Date
MA041544A MA41544A (fr) 2015-02-19 2016-02-16 Dosages de panobinostat pour le traitement du myélome multiple

Country Status (19)

Country Link
US (3) US20190388393A1 (fr)
EP (1) EP3258933A1 (fr)
JP (2) JP2018507216A (fr)
KR (1) KR20170118798A (fr)
CN (1) CN107249596A (fr)
AU (2) AU2016221327A1 (fr)
BR (1) BR112017017594A2 (fr)
CA (1) CA2976755A1 (fr)
CL (1) CL2017002116A1 (fr)
IL (1) IL253895A0 (fr)
MA (1) MA41544A (fr)
MX (1) MX2017010577A (fr)
PH (1) PH12017501494A1 (fr)
RU (1) RU2729425C2 (fr)
SG (1) SG11201706521XA (fr)
TN (1) TN2017000356A1 (fr)
TW (1) TW201630602A (fr)
WO (1) WO2016132303A1 (fr)
ZA (1) ZA201705363B (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110314222B (zh) * 2019-08-07 2023-05-26 上海交通大学医学院附属瑞金医院 硼替佐米和帕比司他或伏立诺他的组合物在制备治疗耐药型mll白血病的药物中的应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1912640T1 (sl) * 2005-08-03 2015-10-30 Novartis Ag Uporaba inhibitorja hdac panobinostata za zdravljenje mieloma
BRPI0712771A2 (pt) 2006-06-12 2012-09-25 Novartis Ag sais de n-hidróxi-3-[4-[[[2-(2-metil-1h-indol-3-il)etil]amino] metil]fenil]-2e-2-propenamida
KR20090110913A (ko) * 2007-02-15 2009-10-23 노파르티스 아게 Lbh589와 암을 치료하기 위한 다른 치료제와의 조합물
US7635707B1 (en) * 2008-11-10 2009-12-22 Intermune, Inc. Pirfenidone treatment for patients with atypical liver function
US8263578B2 (en) * 2010-03-18 2012-09-11 Innopharma, Inc. Stable bortezomib formulations
CN105073115A (zh) * 2013-03-14 2015-11-18 药品循环有限责任公司 布鲁顿氏酪氨酸激酶抑制剂和cyp3a4抑制剂的组合

Also Published As

Publication number Publication date
PH12017501494A1 (en) 2018-01-29
KR20170118798A (ko) 2017-10-25
ZA201705363B (en) 2019-07-31
AU2019200876A1 (en) 2019-02-28
US20200093795A1 (en) 2020-03-26
RU2017132445A3 (fr) 2019-09-23
AU2016221327A1 (en) 2017-08-31
SG11201706521XA (en) 2017-09-28
CA2976755A1 (fr) 2016-08-25
MX2017010577A (es) 2017-12-07
RU2017132445A (ru) 2019-03-20
IL253895A0 (en) 2017-10-31
WO2016132303A1 (fr) 2016-08-25
US20230181529A1 (en) 2023-06-15
TW201630602A (zh) 2016-09-01
CL2017002116A1 (es) 2018-05-18
BR112017017594A2 (pt) 2018-05-08
RU2729425C2 (ru) 2020-08-06
JP2018507216A (ja) 2018-03-15
AU2019200876B2 (en) 2020-05-28
JP2021105048A (ja) 2021-07-26
US20190388393A1 (en) 2019-12-26
EP3258933A1 (fr) 2017-12-27
CN107249596A (zh) 2017-10-13
TN2017000356A1 (en) 2019-01-16

Similar Documents

Publication Publication Date Title
MA49144A (fr) Polythérapies pour le traitement du cancer
MA47501A (fr) Dérivé de di-nucléotides cycliques pour le traitement du cancer
MA43746A (fr) Dérivés de 2-cyanoisoindoline pour le traitement du cancer
MA41449A (fr) Polythérapies pour le traitement de cancers
MA45192A (fr) Traitement d'association
MA43135A (fr) Compositions et méthodes pour le du traitement du cancer
MA45146A (fr) Dérivés de pyrazolopyridine pour le traitement du cancer
MA43283A (fr) Procédés et compositions pour le traitement du cancer
MA39748A (fr) Cenicriviroc pour le traitement de la fibrose
MA45429A (fr) Polythérapie pour le traitement du cancer
FR3046933B1 (fr) Inhibiteurs nlrp3 pour le traitement des pathologies cutanees inflammatoires
MA48637A (fr) Polythérapies pour le traitement du cancer
DK3424534T3 (da) Farmaceutiske sammensætninger til behandling af sygdomme medieret af cystisk fibrosetransmembranledningsregulator
MA55629A (fr) Compositions d'anticorps pour le traitement de tumeurs
MA50409A (fr) Polythérapies pour le traitement du cancer
DK3265421T3 (da) Doseringssystem
MA47719A (fr) Esketamine pour le traitement de la dépression
MA54925A (fr) Compositions pour le traitement de troubles acido-basiques
MA41555A (fr) Polythérapie pour le traitement du cancer
MA51139A (fr) Dérivés de 1-(pipéridinocarbonylméthyl)-2-oxopipérazine pour le traitement du cancer
MA52906A (fr) Procédé de préparation d'amg 416
MA43000A (fr) Polythérapie pour le traitement de tumeurs malignes
MA46963A (fr) Méthodes pour déterminer le dosage de céllules car-t
MA42999A (fr) Polythérapie pour le traitement de malignités
MA41123A (fr) Polythérapie pour le traitement du cancer